{"groups":[{"description":"Participants received 8 milligram per kilogram \\[mg/kg\\] Ramucirumab administered as an intravenous infusion every 2 weeks (Q2W) with 3 doses per 42 day cycle.","id":"FG000","title":"8 mg/kg Ramucirumab (Part A)"},{"description":"Participants received 12 mg/kg Ramucirumab as an intravenous injection Q2W with 3 doses per cycle.","id":"FG001","title":"12 mg/kg Ramucirumab (Part A)"},{"description":"Participants received 12 mg/kg Ramucirumab as an intravenous injection Q2W with 3 doses per cycle.","id":"FG002","title":"12 mg/kg Ramucirumab (Part B)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"4"},{"groupId":"FG002","numSubjects":"0"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}],"type":"Adverse Event"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"15"},{"groupId":"FG002","numSubjects":"6"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"15"},{"groupId":"FG002","numSubjects":"6"}],"type":"Received at Least 1 Dose of Study Drug"},{"achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"10"},{"groupId":"FG002","numSubjects":"6"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Completers included participants who had progressive disease, death due to any cause or alive and on study at conclusion, but off treatment."}